Search Within

Andrew Briggs

  1. "Surgery"
Formats
  1. Meeting Abstract (3)
  2. Journal Article (2)
Groups
  1. Sloan Kettering Institute Postdocs (5)
  2. Surgery (5)
  3. CTCR Scholars (4)
  4. MSK Grad Students (4)
  5. Master of Science in Clinical and Translational Cancer Research (4)
  6. Melanoma Disease Management Team (4)

More Groups

People
  1. Daniel Coit (4)
  2. Edmund Bartlett (4)
  3. Yinin Hu (4)
  4. Charlotte Ariyan (3)
  5. Mary Brady (2)
  6. Michael Marchetti (2)

More People

Years
  1. 2022 (1)
  2. 2020 (2)
  3. 2019 (2)
Publications
  1. Journal of the American College of Surgeons (3)
  2. Annals of Surgical Oncology (1)
  3. European Urology (1)
Publishers
  1. Elsevier Science, Inc. (4)
  2. Springer (1)

Results (5)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Moving beyond PSA: Identifying the optimal diagnostic strategy to assess prostate cancer risk
    Meeting Abstract

    Cheung, D.; Magee, D. E.; Stonier, T.; Briggs, A.; Ferket, B.; Finelli, A.; Kulkarni, G. S.; Vickers, A.; Carlsson, S.; Eastham, J.
    European Urology (2022)

    Fulltext@MSK | Save
  • Sentinel lymph node biopsy for T1b melanoma: Balancing prognostic value and cost
    Journal Article

    Hu, Y.; Briggs, A.; Gennarelli, R. L.; Bartlett, E. K.; Ariyan, C. E.; Coit, D. G.; Brady, M. S.
    Annals of Surgical Oncology (2020)

    Fulltext@MSK | Save
  • Cost-benefit implication of gene expression profiling and adjuvant therapy in stage IIIA melanoma
    Journal Article

    Hu, Y.; Briggs, A.; Marchetti, M. A.; Ariyan, C. E.; Coit, D. G.; Bartlett, E. K.
    Journal of the American College of Surgeons (2020)

    Fulltext@MSK | Save
  • Sentinel lymph node biopsy for T1b melanoma: Balancing prognostic value and cost
    Meeting Abstract

    Hu, Y.; Briggs, A.; Gennarelli, R.; Houghton, S.; Bartlett, E.; Ariyan, C.; Coit, D.; Brady, M. S.
    Journal of the American College of Surgeons (2019)

    Fulltext@MSK | Save
  • Cost-effectiveness of adjuvant therapy for stage IIIA melanoma is poor even when patients are risk-stratified by gene expression profile
    Meeting Abstract

    Hu, Y.; Briggs, A.; Marchetti, M.; Coit, D.; Bartlett, E.
    Journal of the American College of Surgeons (2019)

    Fulltext@MSK | Save